Item 7.01. Regulation FD Disclosure.



On April 4, 2022, PhaseBio Pharmaceuticals, Inc. (the "Company") issued a press
release entitled "PhaseBio Announces Positive Results from Phase 2b Trial for
Bentracimab." The full text of the press release (the "Press Release") is
attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on Form 8-K, including
Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, whether made before
or after the date hereof, except as expressly set forth by specific reference in
such filing to this item of this report.

Item 8.01. Other Events.

On April 4, 2022, the Company issued the Press Release announcing the complete data from its Phase 2b clinical trial of bentracimab.



The Phase 2b clinical trial was a multi-center, randomized, double-blind,
placebo-controlled study, which enrolled a total of 205 older volunteers (50-80
years old), with 154 subjects receiving bentracimab and 51 subjects receiving
placebo, after all were pretreated with dual antiplatelet therapy composed of
ticagrelor and low-dose aspirin.

The primary efficacy endpoint for the Phase 2b clinical trial was reversal of
ticagrelor's inhibition of platelet function in actively treated subjects versus
placebo as measured using the point-of-care VerifyNow® PRUTest® platelet
function assay (VerifyNow). In the Phase 2b clinical trial, bentracimab
significantly restored platelet function within five minutes of administration
(p<0.001), as measured by multiple assays including VerifyNow. The reversal
results were tightly correlated across all assays used in the study to measure
platelet function.

There were no drug-related serious adverse events or thrombotic events reported
in the Phase 2b clinical trial. Overall, bentracimab appeared well tolerated,
with subjects reporting only non-serious adverse events. The most-commonly
reported adverse events were injection site bruising and headache, with similar
rates seen in both the placebo and active-treatment arms. There was no
significant difference between bentracimab and placebo for any of the adverse
events reported.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


    Exhibit No.                                            Description

99.1                         Press Release, dated April 4, 2022, entitled

"PhaseBio Announces Positive


                           Results from Phase 2b Trial for Bentracimab".

104                        Cover page interactive data file (formatted as Inline XBRL).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses